Argenica Therapeutics (ASX: AGN) gears up for clinical trial of promising novel stroke treatment (w/ Liz Dallimore)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Argenica Therapeutics (ASX: AGN) chief executive officer Dr Liz Dallimore joins Small Caps to discuss the company's upcoming phase 1 clinical trials evaluating its novel drug candidate in stroke patients. The drug is designed to be administered by first responders to protect the brain following stroke and has achieved successful outcomes in pre-clinical studies. Argenica has raised $7 million in an IPO and will list on the ASX Friday 11 June 2021.